Katsuaki Maehara: Japanese Perspective on 10-Year Follow-Up and Cure After Adjuvant Osimertinib in Lung Cancer
Katsuaki Maehara/X

Katsuaki Maehara: Japanese Perspective on 10-Year Follow-Up and Cure After Adjuvant Osimertinib in Lung Cancer

Katsuaki Maehara, Director of Medical Education Colleagues in Tokyo, shared on X:

“Osimertinib – ADAURA

Although recurrence and mortality rates have been increasing over time, the magnitude of the HR has remained stable. Japanese thoracic surgeons inform patients that the condition is considered cured if there is no recurrence 10 years after surgery. They say that 5 years is too short a period.

Katsuaki Maehara: Japanese Perspective on 10-Year Follow-Up and Cure After Adjuvant Osimertinib in Lung Cancer

This is an IMO. I’m not sure how far the follow-up will go, but I’d like to see the DFS update. If we can determine the cure rate, the significance and value of postoperative adjuvant therapy will become clearer.”

Find out more:

ADAURA at WCLC 2026: 8-Year Survival Confirms Durable Benefit of Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC

Katsuaki Maehara: Japanese Perspective on 10-Year Follow-Up and Cure After Adjuvant Osimertinib in Lung Cancer